Hypoglycaemia Neonatal

43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (0.5 ml / kg)

Administration of a placebo solution (0.5 ml / kg)

43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (1 ml / kg)

Administration of a placebo solution (1 ml / kg)

43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (0.5 ml / Kg)

Administration of 40% glucose in gel (0.5 ml / Kg)

43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (1 ml / Kg).

Administration of 40% glucose in gel 1 ml / Kg)

Poliambulanza Foundation Hospital Institute

Prevention of Hypoglycaemia by Oral 40% Destrogel

Use of Oral 40% Destrogel to Prevent Hypoglycaemia in Late-term Births and SGA or LGA Term Newborns

To assess whether a single administration of Destrogel 40% micronutrient can reduce the incidence of hypoglycaemia in late term newborns and in SGA and LGA term infants (gestational age: 37-42 weeks).

To evaluate whether the administration of the 40% micronutrient Destrogel is able to decrease the incidence of the use of formula milk and the intravenous administration of 10% glucose solution in late term infants and in SGA and LGA term newborns (gestational age: 37-42 weeks), reducing artificial breastfeeding in favour of breastfeeding and also reducing the pain of the newborn during the execution of peripheral venous access for the administration of hypoglycaemia therapy.

Giuseppe De Bernando

Principal Investigator

Fondazione Poliambulanza Istituto Ospedaliero

Type 1 Diabetes

Damien JOLLY

Continuous Glucose Monitoring and Hypoglycemia Unawareness in Type 1 Diabetes

Continuous Glucose Monitoring and Hypoglycemia Unawareness in Type 1 Diabetes: a Pilot Study

CHU de Reims

Pediatric Dilated Cardiomyopathy

treatment of anemia.

A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy

Through clinical manifestations of heart of heart failure and echocardiographic assesment of ventricular function

To measure health related quality of life, to monitor the health of populations over time, or to evaluate the efficacy and effectiveness of clinical therapies of practices using a preference weighted self administered measure.

Mohamed Ahmed Amar

principal investigator

Assiut University

We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.

Japanese Encephalitis

IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.
Placebo group received 0.9% saline intravenous at similar rate.

Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]

Kanti Children's Hospital

BP Koirala Institute of Health Sciences

Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis

A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal

Patients will be monitored for side effects such as infusion site reaction, diarrhea, rise in blood pressure (in mm Hg) and change in urinary output (in ml/Kg/hour) every 12 hours from first day of commencing treatment until until death or discharge. Patient on average are administered the study drug on the first day of admission. The study drug is administered daily for 5 days. Patients are discharged on an average on eighth day (192 hours) of hospital admission.

At the time of discharge(expected average of eighth day of admission) or death: Time to death, to recover from coma, to sit independently, to stand independently, to walk at least 5m independently, and to leave hospital.
At 6 months after discharge: history of further seizures, behavioral changes, evidence of recovery of neurological sequelae such as assessment of ability to sit independently, to stand independently, to walk at least 5 meters independently.

Pre-treatment was immediately prior to the first dose of study drug on the first day, mid-treatment was immediately prior to the 4th dose and post-treatment was 1hour after administering the fifth dose of the study drug.

pallor/seizures

Prevention of Hypoglycaemia by Oral 40% Destrogel

Continuous Glucose Monitoring and Hypoglycemia Unawareness in Type 1 Diabetes

A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy

Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne